23 de septiembre de 2026
The FDA approved Lyrfigtu (lirafugratinib hydrochloride), a drug from Elevar. Form: Capsule, Oral. Granted priority review, reserved for treatments that would be a significant improvement over what exists. Application NDA220425.
Calendario de Aprobaciones de nuevos medicamentos de la FDA